TOP > 外国特許検索 > CYCLIC SINGLE-CHAIN ANTIBODY

CYCLIC SINGLE-CHAIN ANTIBODY

外国特許コード F200010150
整理番号 S2018-0765-C0
掲載日 2020年6月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP026983
国際公開番号 WO 2020013126
国際出願日 令和元年7月8日(2019.7.8)
国際公開日 令和2年1月16日(2020.1.16)
優先権データ
  • 特願2018-130203 (2018.7.9) JP
発明の名称 (英語) CYCLIC SINGLE-CHAIN ANTIBODY
発明の概要(英語) Provided is a cyclic scFv wherein the N-terminus of an scFv, in which the heavy chain variable region (VH) is linked to the light chain variable region via a first peptide linker, is linked to the C-terminus thereof via a second peptide linker.
従来技術、競合技術の概要(英語) BACKGROUND ART
Monoclonal antibodies, oncology, chronic inflammatory diseases, transplant, infection, a cardiovascular physician, or ophthalmic diseases in various clinical use as therapeutic agents, in addition, the inspection agent, such as the sensor element, being used in various applications. The main function of an antibody specific for an antigen (target molecule) and binding, antigen, Fv are recognized by the domain.
From the heavy chain Fv antibody Fv domains of the Fv (VH) and a light chain derived from the domain of the domain from (VL). Fv antibody domain has been extracted from the fragment in the target antibody Fv fragment number and the ability to bind to, the minimum unit of an antibody antigen-binding function of the form. Single-chain antibody (scFv: single-chain Fv) VL and VH is connected by a peptide linker to the present invention. For example, advanced glycation end products (AGEs) scFv recognize has been reported (Non-Patent Document 1).
Such as CHO cells or hybridoma monoclonal antibody is typically a eukaryotic cell from the used in production, a great cost is required for the production. ScFv about 25kDa molecular weight, molecular weight as compared with the full-length antibodies are very small. Therefore, such as E. coli as a host prokaryotic or eukaryotic organism can be produced and used, as compared with the length of the scFv antibody production has advantages in terms of cost.
Also corresponds to a trimer of scFv annular stranded trispecific antibodies are also been reported (Patent Document 1). ScFv is generally associated with the other hand forming a multimer has the property, the scFv to form the dimer, trimer, and tetramer has been reported in relation to the (non-patent document 2-4). Thus easily forming a multimer scFv the property that, in terms of improvement in the stability of scFv has been a problem.
The stability of the antibody molecule include the meaning of the one 3. The first is the heat resistance or thermal stability and, the second is the stability and proteolytic enzymes, and the third is due to suppress the formation of an aggregate storage stability. ScFv is particularly a problem in storage stability if it has.
In a modification of the peptide sortase and have been reported a method using (Patent Document 2 and 3, and 6 and Non-Patent Document 5), using the methods for synthesis of the cyclic peptide sortase has been reported (Non-Patent Document 7) is.
Nintein, intein and the central portion, which sandwich (exteins) configured by the sequence. Nintein, intein from the cut portion of the self-host sequences, flanking the peptide bond cleavage by a reaction (exteins) connecting the internal protein factors. Results in the reaction, the enzyme does not require auxiliary or cofactors in the post-translational processes (non-patent document 8). Arranged upstream of an intein exteins sequence ' N- exteins' is referred to as, and disposed downstream of an intein exteins' C- exteins' is called. As the reaction product of an intein, one 2 of the mature protein cleavage can be obtained stable proteins.
Nintein, can be divided into two, and, 2 and two separate transcription and translation of the one encoded by the gene can be present as a fragment 2. Referred to as split intein Nintein divided, self-association, and linked by a peptide bond to N- C - exteins exteins protein splicing reaction to the catalyst. Split intein is, the division results in artificially can be manufactured. And also present in the natural, and archaebacterial plasfocjanin various been confirmed in the (non-patent document 9-14). Nostoc punctiforme DnaE (NpuDnaE) is derived from, have been reported in non-patent document is the highest reaction efficiency in the split intein Nintein (non-patent document 14 and 15). Cleavage reaction and a cyclization reaction of the protein of interest also can be used as has been reported (Patent Document 4 and 5).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • MORIOKA HIROSHI
  • KOBASHIGAWA YOSHIHIRO
  • SATO TAKASHI
  • FUKUDA NATSUKI
  • YAMAUCHI SOICHIRO
国際特許分類(IPC)
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close